Asymptomatic  ||| S:0 E:13 ||| JJ
primary  ||| S:13 E:21 ||| JJ
hyperparathyroidism ||| S:21 E:40 ||| NN
:  ||| S:40 E:42 ||| :
surgical  ||| S:42 E:51 ||| JJ
and  ||| S:51 E:55 ||| CC
medical  ||| S:55 E:63 ||| JJ
management  ||| S:63 E:74 ||| NN
Primary  ||| S:74 E:82 ||| JJ
hyperparathyroidism  ||| S:82 E:102 ||| NNS
( ||| S:102 E:103 ||| -LRB-
PHPT ||| S:103 E:107 ||| NNP
)  ||| S:107 E:109 ||| -RRB-
is  ||| S:109 E:112 ||| VBZ
a  ||| S:112 E:114 ||| DT
common  ||| S:114 E:121 ||| JJ
endocrine  ||| S:121 E:131 ||| JJ
disorder ||| S:131 E:139 ||| NN
,  ||| S:139 E:141 ||| ,
frequently  ||| S:141 E:152 ||| RB
asymptomatic ||| S:152 E:164 ||| VBN
.  ||| S:164 E:166 ||| .
Notwithstanding ||| S:166 E:181 ||| RB
,  ||| S:181 E:183 ||| ,
mild  ||| S:183 E:188 ||| JJ
PHPT  ||| S:188 E:193 ||| NNP
may  ||| S:193 E:197 ||| MD
cause  ||| S:197 E:203 ||| VB
adverse  ||| S:203 E:211 ||| JJ
skeletal  ||| S:211 E:220 ||| JJ
effects  ||| S:220 E:228 ||| NNS
that  ||| S:228 E:233 ||| WDT
include  ||| S:233 E:241 ||| VBP
high  ||| S:241 E:246 ||| JJ
bone  ||| S:246 E:251 ||| NN
remodeling ||| S:251 E:261 ||| NN
,  ||| S:261 E:263 ||| ,
reduced  ||| S:263 E:271 ||| VBN
bone  ||| S:271 E:276 ||| NN
mineral  ||| S:276 E:284 ||| NN
density  ||| S:284 E:292 ||| NNS
( ||| S:292 E:293 ||| -LRB-
BMD ||| S:293 E:296 ||| NNP
) ||| S:296 E:297 ||| -RRB-
,  ||| S:297 E:299 ||| ,
and  ||| S:299 E:303 ||| CC
increased  ||| S:303 E:313 ||| VBD
fracture  ||| S:313 E:322 ||| JJ
risk ||| S:322 E:326 ||| NN
.  ||| S:326 E:328 ||| .
The  ||| S:328 E:332 ||| DT
definitive  ||| S:332 E:343 ||| JJ
therapy  ||| S:343 E:351 ||| NN
for  ||| S:351 E:355 ||| IN
symptomatic  ||| S:355 E:367 ||| NN
and  ||| S:367 E:371 ||| CC
asymptomatic  ||| S:371 E:384 ||| JJ
PHPT  ||| S:384 E:389 ||| NNP
( ||| S:389 E:390 ||| -LRB-
aPHPT ||| S:390 E:395 ||| NNP
)  ||| S:395 E:397 ||| -RRB-
is  ||| S:397 E:400 ||| VBZ
parathyroidectomy ||| S:400 E:417 ||| VBN
,  ||| S:417 E:419 ||| ,
which  ||| S:419 E:425 ||| WDT
has  ||| S:425 E:429 ||| VBZ
been  ||| S:429 E:434 ||| VBN
shown  ||| S:434 E:440 ||| VBN
to  ||| S:440 E:443 ||| TO
increase  ||| S:443 E:452 ||| VB
BMD ||| S:452 E:455 ||| NNP
.  ||| S:455 E:457 ||| .
In  ||| S:457 E:460 ||| IN
patients  ||| S:460 E:469 ||| NNS
who  ||| S:469 E:473 ||| WP
choose  ||| S:473 E:480 ||| VBP
not  ||| S:480 E:484 ||| RB
to  ||| S:484 E:487 ||| TO
be  ||| S:487 E:490 ||| VB
treated  ||| S:490 E:498 ||| VBN
surgically  ||| S:498 E:509 ||| NNS
or  ||| S:509 E:512 ||| CC
have  ||| S:512 E:517 ||| VBP
contraindications  ||| S:517 E:535 ||| VBN
for  ||| S:535 E:539 ||| IN
surgery ||| S:539 E:546 ||| NN
,  ||| S:546 E:548 ||| ,
medical  ||| S:548 E:556 ||| JJ
therapy  ||| S:556 E:564 ||| NN
should  ||| S:564 E:571 ||| MD
include  ||| S:571 E:579 ||| VB
drugs  ||| S:579 E:585 ||| NNS
designed  ||| S:585 E:594 ||| VBN
to  ||| S:594 E:597 ||| TO
protect  ||| S:597 E:605 ||| VB
the  ||| S:605 E:609 ||| DT
skeleton  ||| S:609 E:618 ||| NN
and ||| S:618 E:621 ||| CC
/ ||| S:621 E:622 ||| NNP
or  ||| S:622 E:625 ||| CC
to  ||| S:625 E:628 ||| TO
lower  ||| S:628 E:634 ||| VB
serum  ||| S:634 E:640 ||| JJ
calcium ||| S:640 E:647 ||| NN
,  ||| S:647 E:649 ||| ,
such  ||| S:649 E:654 ||| JJ
as  ||| S:654 E:657 ||| IN
bisphosphonates ||| S:657 E:672 ||| NN
,  ||| S:672 E:674 ||| ,
hormone  ||| S:674 E:682 ||| JJ
replacement ||| S:682 E:693 ||| NN
,  ||| S:693 E:695 ||| ,
and ||| S:695 E:698 ||| CC
/ ||| S:698 E:699 ||| NNP
or  ||| S:699 E:702 ||| CC
calcimimetic  ||| S:702 E:715 ||| JJ
agents ||| S:715 E:721 ||| NNS
.  ||| S:721 E:723 ||| .
However ||| S:723 E:730 ||| RB
,  ||| S:730 E:732 ||| ,
there  ||| S:732 E:738 ||| EX
are  ||| S:738 E:742 ||| VBP
currently  ||| S:742 E:752 ||| RB
no  ||| S:752 E:755 ||| DT
fracture  ||| S:755 E:764 ||| JJ
data  ||| S:764 E:769 ||| NNS
for  ||| S:769 E:773 ||| IN
any  ||| S:773 E:777 ||| DT
of  ||| S:777 E:780 ||| IN
these  ||| S:780 E:786 ||| DT
options ||| S:786 E:793 ||| NNS
.  ||| S:793 E:795 ||| .
Obviously ||| S:795 E:804 ||| RB
,  ||| S:804 E:806 ||| ,
there  ||| S:806 E:812 ||| EX
is  ||| S:812 E:815 ||| VBZ
the  ||| S:815 E:819 ||| DT
need  ||| S:819 E:824 ||| NN
for  ||| S:824 E:828 ||| IN
larger  ||| S:828 E:835 ||| JJR
randomized  ||| S:835 E:846 ||| NNS
controlled  ||| S:846 E:857 ||| VBN
trials  ||| S:857 E:864 ||| NNS
with  ||| S:864 E:869 ||| IN
fractures  ||| S:869 E:879 ||| NN
as  ||| S:879 E:882 ||| IN
end-points  ||| S:882 E:893 ||| JJ
to  ||| S:893 E:896 ||| TO
evaluate  ||| S:896 E:905 ||| VB
the  ||| S:905 E:909 ||| DT
efficacy  ||| S:909 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
medical  ||| S:921 E:929 ||| JJ
treatment ||| S:929 E:938 ||| NN
.  ||| S:938 E:940 ||| .
